Kanna and CBD: How Two Calming Botanicals Compare and Combine

The wellness world is buzzing with options for natural stress relief, but two plants keep rising to the top of the conversation: kanna and CBD. 

Both come from ancient botanical traditions, both carry reputations for calming the nervous system, and both have found their way into supplements, tinctures, and functional beverages. Yet despite their shared popularity, they work through entirely different pathways in the body, serve different purposes, and offer distinct experiences.

If you have been trying to make sense of the kanna vs. CBD conversation, or wondering whether these two herbs can work together, you are in the right place. This article breaks down the science, the history, and the key differences between the two, so you can make an informed choice about what belongs in your wellness routine. 

And if you are curious about a ready-to-drink option that leads with kanna at its core, Kamello’s canned beverages might be a good place to start.

Two Plants, Two Completely Different Theories of Calm

Kanna: A 5,000-Year-Old Mood Hack from South Africa

Kanna, the common name for Sceletium tortuosum, is a succulent native to South Africa with a history of use stretching back centuries among the indigenous Khoi and San peoples. 

Traditionally chewed, brewed as tea, or used as snuff, kanna was relied upon for its ability to ease tension, reduce hunger and thirst during long journeys, and foster social connection during gatherings.

Modern research has confirmed much of what traditional users already knew. The plant's active constituents are mesembrine-type alkaloids, and research published in PMC shows they act on serotonin reuptake and the PDE4 enzyme to produce effects that simultaneously elevate mood and support cognitive clarity.

Kanna also acts as a CYP17A1 inhibitor, an enzyme involved in cortisol synthesis, suggesting the plant targets the body's primary stress hormone at its source rather than just soothing the emotional fallout.

CBD: Calm from the Inside Out

CBD (cannabidiol) is derived from the Cannabis sativa plant and is the most abundant non-psychoactive cannabinoid found in hemp. 

Unlike THC, CBD does not produce intoxication. Instead, it operates through the body's endocannabinoid system (ECS), a network of receptors that helps regulate mood, pain, sleep, immune function, and the body's reaction to stress.

Rather than binding directly to CB1 or CB2 receptors the way THC does, CBD facilitates endocannabinoid signaling by inhibiting the breakdown of anandamide, a naturally occurring "bliss molecule." It also activates serotonin 5-HT1A receptors, the same receptor class targeted by buspirone, a commonly prescribed anti-anxiety medication.

Research published in Neurotherapeutics found that this 5-HT1A activity contributes to CBD's calming properties, and helps explain why it shares some anxiolytic ground with kanna despite working through an entirely separate system. 

For people exploring Kamello's approach to functional calm, understanding this overlap is useful grounding.

The Science Behind the Serenity

Kanna's Pathway: Serotonin, PDE4, and the Mood Lift Mechanism

Kanna's mesembrine alkaloids, particularly mesembrine and mesembrenone, work as serotonin reuptake inhibitors similar in mechanism to several modern antidepressants, while also inhibiting the PDE4 enzyme. 

PDE4 inhibition suppresses the production of inflammatory cytokines, so kanna carries mild anti-inflammatory properties alongside its mood-enhancing ones. Harvey et al., 2011 in the Journal of Ethnopharmacology documented these multi-target pharmacological actions in detail, establishing the scientific case for kanna's broad range of activity.

It is also worth noting that kanna is a multi-alkaloid plant whose compounds appear to work synergistically. 

This concept, sometimes called the entourage effect, was described for cannabis phytocannabinoids by Russo, 2011 in the British Journal of Pharmacology and applies somewhat here: kanna's mesembrine, mesembrenone, and mesembrenol likely produce a richer result together than any single isolated compound would. 

The same logic extends to CBD, making full-spectrum formulation quality relevant for both plants.

CBD's Pathway: Riding the Endocannabinoid Wave

While kanna engages serotonin pathways, CBD modulates the body through an entirely separate system. 

By blocking the FAAH enzyme, CBD prevents anandamide from breaking down, indirectly supporting emotional balance and reducing inflammation without directly activating cannabinoid receptors. It also interacts with TRPV1 receptors, which play a key role in pain signaling, giving CBD a broader physiological reach than kanna.

One underappreciated consideration is absorption. Oral CBD has low and variable bioavailability, estimated at 6–19%, due to first-pass liver metabolism and its high lipophilicity. Sublingual and inhaled formats bypass much of this first-pass effect and get the compound into the bloodstream faster.

Onset for oral or beverage-format CBD typically ranges from 45 to 90 minutes, compared to 15 to 45 minutes for sublingual oils, a gap worth knowing when timing matters.

Same Goal, Wildly Different Routes

Shared Territory: Where Kanna and CBD Meet

Both herbs have been studied for their potential to ease anxiety and support resilience under pressure. 

A systematic review in PMC found that preliminary human trial data supports CBD's calming effects, while PMC-indexed research on Sceletium tortuosum documents consistent evidence for its role in reducing anxiety and depressive symptoms across experimental and clinical models.

The experiential overlap is real: people using either plant commonly report a softening of the acute edge of stress, greater ease in social settings, and a quieting of anxious rumination.

For those seeking alcohol alternatives or functional beverages that deliver something tangible, both offer genuine territory. This is exactly the space that Kamello occupies, providing the grounded calm of kava alongside the social uplift of kanna in every can.

Where the Experience Splits: Uplift vs. Ease

The sharpest divergence is in how each plant feels. 

Kanna leans uplifting. Its serotonin-driven character tends to produce a noticeable brightening of mood, heightened sociability, and a sense of warm, open engagement. 

CBD leans settling. Its ECS-mediated effects bring physical relaxation, reduced bodily tension, and a quieter nervous system, usually without any shift in emotional energy.

In practice: someone navigating social anxiety before an event may find kanna's warmth and lift more useful in the moment. Someone releasing physical tension at the end of the day may find CBD's body-level settling more fitting. Their mechanisms are different enough that they function as genuinely different tools rather than swappable alternatives.

Two Botanicals, One Ritual: The Case for Combining Them

The Case for Complementary Use

Because kanna targets the serotonergic system and CBD targets the endocannabinoid system, there is no known direct adverse interaction between the two based on their respective mechanisms. Some people intentionally combine them for what they describe as a balanced experience: the mood lift from kanna alongside the bodily ease from CBD.

The logic holds up mechanistically: one addresses the cognitive and emotional side of tension, the other the physical and systemic side, covering more ground together than either would alone.

Research into the crosstalk between serotonergic and endocannabinoid signaling is ongoing. While formal studies on this pairing are limited, the mechanistic separation suggests a low likelihood of direct interference. 

For kanna in particular, standardized extracts with verified alkaloid percentages and third-party certificates of analysis offer more predictable results than unverified raw materials.

What to Keep in Mind Before You Mix

Anyone taking prescription medications that act on serotonin, including SSRIs, SNRIs, or MAOIs, should speak with a healthcare professional before adding kanna. The concern is serotonin syndrome, a condition that can develop when serotonergic activity in the brain becomes excessive.

A foundational review by Boyer and Shannon, 2005 in the New England Journal of Medicine describes a spectrum of symptoms ranging from agitation, tremor, and elevated heart rate in milder presentations to hyperthermia and seizures in severe cases. 

This is not a kanna-specific risk but a general caution for any substance that substantially raises serotonin availability alongside existing serotonergic medications.

It is also worth noting that the FDA has not approved CBD as a food or dietary supplement ingredient and continues to assess its safety in these formats. ScienceDirect notes that kanna shows a relatively low side effect profile clinically, though elevated blood pressure, nausea, and headache have been reported at higher doses. 

Starting conservatively, tracking your response, and choosing transparently formulated products are sensible standards for either compound.

What the Research Reveals

Kanna Under the Microscope: Clinical and Preclinical Findings

A landmark 2013 study in Neuropsychopharmacology found that a single 25mg dose of a standardized Sceletium tortuosum extract reduced threat-related amygdala reactivity and attenuated amygdala-hypothalamus coupling in healthy volunteers. 

This was the first neuroimaging evidence that kanna modulates the brain's threat-processing circuitry directly, providing a biological basis for centuries of traditional use.

A separate toxicological safety study in PubMed found no mortality or treatment-related adverse effects in rats across both 14-day and 90-day study periods.

Preclinical work has also found that mesembrine-based extracts showed no reinforcing effects in conditioned place preference models, suggesting a low likelihood of dependency potential, an important data point as kanna gains traction in consumer wellness markets.

CBD's Expanding Evidence Base

CBD has accumulated a considerably larger body of clinical evidence than kanna, reflecting both its earlier commercial entry and the decades of research into cannabis. 

A systematic review in PMC found that across randomized controlled trials, CBD reduced anxiety symptoms with minimal adverse effects compared to placebo.

Seven double-blind, placebo-controlled trials covering 232 participants supported CBD as a promising regulator of the body's stress axis through the endocannabinoid system. Kanna's clinical trial pipeline is smaller by comparison, but growing steadily as Western research interest catches up with its long ethnobotanical record.

One Opens the Room. The Other Turns Down the Volume. Here's How to Choose.

Both kanna and CBD represent a broader cultural shift: the move toward plant-based, non-intoxicating tools for managing the weight of everyday stress and the need to simply unwind. Neither is a pharmaceutical, and neither should replace clinical care for diagnosed conditions.

But as part of a thoughtful wellness routine, both offer real, well-documented value. The distinction worth holding onto is this: kanna opens and uplifts, CBD settles and eases. One brightens the room; the other turns down the volume.

Depending on what your moment calls for, one may serve you better than the other, and in some contexts they may work best as a considered pair. 

At Kamello, the goal is to bring kanna into a format that fits modern life without ceremony or complexity. Paired with noble kava in a ready-to-drink can, it delivers grounded calm and genuine mood support in flavors like Citrus Blossom, Peach and Black Tea, and Spiced Coffee. 

Ancient roots. Modern chill. Explore the full lineup today and discover your new ritual..

Frequently Asked Questions

Is kanna legal in the United States?

Kanna, also called Sceletium tortuosum, is not treated like cannabis, THC, opioids, or other scheduled drugs under ordinary federal consumer-drug categories. 

The Drug Enforcement Administration explains that controlled substances are placed into federal schedules based on factors such as accepted medical use and abuse or dependence potential, and kanna is not commonly listed among those scheduled drug categories in federal drug-testing or controlled-substance discussions through the DEA’s drug scheduling overview.

That said, “not federally scheduled” is not the same thing as FDA approved. 

Kanna products sold as capsules, extracts, powders, or beverages may be marketed in the wellness space, but the FDA explains that dietary supplements are regulated differently from prescription or over-the-counter drugs, and they are not approved by FDA for the diagnosis, treatment, cure, or prevention of disease through the agency’s dietary supplement guidance.

The most accurate way to think about kanna in the United States is this: it is generally available in consumer products, but product legality depends on how it is formulated, labeled, marketed, and sold. 

Disease-treatment claims, unsafe ingredients, poor manufacturing practices, or state-specific restrictions can change the regulatory picture even when the plant itself is not handled like a scheduled drug.

For consumers, the practical takeaway is to buy from transparent brands that clearly identify the botanical name, serving size, alkaloid standardization, and third-party testing. 

If you live in a state with stricter rules around psychoactive botanicals or are subject to workplace, athletic, military, or probation-related restrictions, it is wise to check the rules that apply to your situation before purchasing or using kanna.

Does kanna show up on a drug test?

Kanna’s primary alkaloids, including mesembrine-type compounds, are not part of the standard federal workplace drug-testing panel. 

Federal workplace testing programs focus on specific drug classes such as marijuana metabolites, cocaine metabolites, opioids, amphetamines, and PCP, as outlined in SAMHSA’s workplace drug testing resources.

That means a standard drug screen is not designed to look for kanna in the way it is designed to look for THC, cocaine, opioids, amphetamines, or similar controlled substances. However, no drug-testing answer should be treated as a guarantee. 

Employers, athletic organizations, courts, or medical programs can use expanded or specialized panels, and testing requirements can vary widely.

The bigger practical risk is not usually kanna itself, but product quality. Poorly made botanical products may be mislabeled, contaminated, or blended with ingredients that are not obvious on the front label. 

This concern is especially relevant when products also contain CBD, because the FDA has warned that cannabis-derived products can raise quality, labeling, and safety concerns, including questions about THC content, through its CBD regulation and safety overview.

If drug testing matters for your job, sport, license, or legal status, choose products with current certificates of analysis from an independent lab and avoid products that do not clearly disclose all active ingredients. If the test has serious consequences, it is safest to ask the testing administrator what substances are included rather than relying on general consumer guidance.

Does CBD interact with common medications beyond serotonergic drugs?

Yes. CBD can interact with medications beyond antidepressants and other serotonin-active drugs, but the level of concern depends on the medication, dose, route of use, liver function, and how narrow the medication’s safety margin is. 

A peer-reviewed systematic review of cannabinoid drug interactions explains that cannabinoids, including CBD, can involve liver enzymes such as CYP3A4, CYP2C9, and CYP2C19, which are also involved in the metabolism of many prescription medications. Clinically important examples include some anti-seizure medications, sedatives, immunosuppressants, and drugs where small blood-level changes can matter. 

The FDA-approved prescribing information for pharmaceutical cannabidiol describes a three-fold increase in the active metabolite of clobazam, higher risk of liver enzyme elevations with valproate, and potential increases in drugs such as tacrolimus, sirolimus, or everolimus through the Epidiolex prescribing information.

CBD also has safety considerations that are not limited to metabolism. Pharmaceutical cannabidiol labeling describes dose-related liver enzyme elevations, somnolence, sedation, and warnings about driving or operating machinery until a person knows how it affects them. 

Those warnings come from studies of a prescription CBD product at medical doses, so they do not translate perfectly to every consumer CBD product, but they show why CBD should not be treated as automatically interaction-free.

Anyone taking prescription medication, especially blood thinners, anti-seizure drugs, sedatives, transplant medications, heart medications, or drugs with narrow therapeutic windows, should ask a pharmacist or healthcare professional before using CBD regularly. This is especially important with daily use, high-dose CBD, liver disease, alcohol use, or multiple medications.

Can kanna and CBD be taken with alcohol?

Kanna and CBD are better understood as alcohol alternatives than alcohol add-ons. Alcohol can impair coordination, attention, reaction time, and judgment, and it can interact with many medications and sedating substances. 

The National Institute on Alcohol Abuse and Alcoholism explains that alcohol can have harmful interactions with a wide range of medicines, including those that affect sleep, mood, pain, allergies, and the central nervous system, in its alcohol and medication interaction guidance.

For CBD, the caution is more direct. FDA-approved cannabidiol labeling states that other central nervous system depressants, including alcohol, may increase the risk of sedation and somnolence, and it advises caution around driving or operating machinery until the user understands how cannabidiol affects them.

For kanna, there is much less direct human research on alcohol-combination use. Because kanna contains psychoactive mesembrine-type alkaloids and has been studied for serotonin transporter and PDE4-related activity, caution is appropriate even though the exact risks of combining kanna with alcohol have not been well defined in controlled human trials. 

A pharmacology study of Sceletium tortuosum extract reported activity involving the serotonin transporter and PDE4, which supports treating it as an active botanical rather than a neutral flavoring ingredient.

The safest recommendation is to avoid mixing alcohol with kanna or CBD, especially before driving, when using medications, or when you do not yet know how either botanical affects you. If someone chooses to drink alcohol, they should avoid stacking it with other calming, sedating, or psychoactive substances and should not drive afterward.

How does fermentation affect kanna’s potency? 

Fermentation is part of the traditional preparation history of kanna, but it should not be treated as a simple guarantee of “stronger” or “better.” Research on fermented Sceletium tortuosum plant material found that preparation can change the plant’s phytochemical profile, including alkaloid composition.

The more precise claim is that fermentation may change alkaloid ratios, not that it automatically improves human absorption or produces a predictable effect. Human bioavailability data for different kanna preparations remain limited, so claims that fermentation “enhances bioavailability” should be made cautiously unless a specific product has direct evidence to support that claim.

Modern kanna extracts can also be standardized without relying on vague fermentation language. Standardization matters because kanna contains multiple mesembrine-type alkaloids, and reviews of mesembrine alkaloids describe these compounds as important contributors to the plant’s biological activity.

For consumers, the most useful quality marker is not simply whether a product says “fermented.” A more reliable product should identify the extract, list the amount per serving, disclose alkaloid standardization when applicable, and provide a current third-party certificate of analysis showing identity, potency, and contaminant testing.

Is the “entourage effect” the same for kanna as it is for cannabis?

Not exactly. The phrase “entourage effect” comes from cannabis research, where it is often used to describe how cannabinoids, terpenes, and other plant compounds may influence the overall effect of a cannabis product. 

Kanna is a different plant with different chemistry, so the cannabis model should not be copied onto kanna as if the same receptor systems and evidence base apply. A better way to describe kanna is “multi-alkaloid activity.” 

Kanna contains mesembrine, mesembrenone, mesembrenol, and related alkaloids, and pharmacology research has reported activity involving targets such as the serotonin transporter and PDE4 in Sceletium tortuosum extract.

There is some scientific support for the idea that different kanna constituents may contribute differently to the overall effect. A 2024 study reported that mesembrine significantly contributed to anxiolytic effects in the studied model, while antidepressant-like effects may require synergy among multiple plant constituents.

So, the concept of whole-plant complexity may be relevant to kanna, but it should be described carefully. Kanna’s effects should be explained through its own alkaloids, its own pharmacology, and the limited but growing evidence specific to Sceletium tortuosum, rather than borrowing cannabis terminology too broadly.